Lipika Goyal, MD, on Treating Intrahepatic Cholangiocarcinoma With Futibatinib 
    		AACR Annual Meeting 2021
    	
    	
    	
    
        Lipika Goyal, MD, of Massachusetts General Hospital, discusses phase II results of the FOENIX-CCA2 trial, which explored the clinical benefit of futibatinib, an FGFR1–4 inhibitor, tested in patients with intrahepatic cholangiocarcinoma that harbored FGFR2 gene fusions or other rearrangements (Abstract CT010).
    
    
    
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Joann G. Elmore, MD, MPH, of the UCLA Fielding School of Public Health, discusses previous studies that show wide variability in cancer diagnoses, the uncertainties introduced by computer-aided detection tools, and new research on artificial intelligence and machine learning that may lead to more consistent and accurate diagnoses and prognoses, potentially improving treatment (Abstract SY01-03).
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Katelyn T. Byrne, PhD, of the Perelman School of Medicine at the University of Pennsylvania, discusses the first in-depth analysis of the impact of selicrelumab, an anti-CD40 antibody, which was found to enrich T cells in pancreatic tumors, activate the immune system, and alter the tumor stroma (Abstract CT005).
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Richard S. Finn, MD, of UCLA Medical Center, discusses updated efficacy and safety data from the IMbrave150 trial of patients receiving atezolizumab plus bevacizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma (Abstract CT009).
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Linda T. Vahdat, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses results of a phase II trial designed to test the concept that targeting the tumor microenvironment by depleting copper may prevent metastases, essentially disrupting the infrastructure that contributes to tumor spread.
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a variety of RET fusion–positive cancers, including treatment-refractory gastrointestinal malignancies. This analysis highlights the need for genomic profiling to identify actionable oncogenic drivers.